论文部分内容阅读
近年来,我院应用瑞替辅酶(rPA)静脉溶栓治疗急性心肌梗死(AMI)患者65例,本文回顾性分析rPA治疗AMI的临床疗效及安全性。现报告如下。1资料与方法1.1临床资料2012年8月至2014年6月我院收治的AMI患者65例,男52例、女13例,年龄31~75岁、平均(55.8±10.5)岁;均临床表现有胸痛、胸闷、气短、呼吸困难等,其中伴有
In recent years, our hospital application of intravenous thrombolysis rituximab (rPA) in patients with acute myocardial infarction (AMI) in 65 cases, this paper retrospectively analyzed the clinical efficacy and safety of rPA in the treatment of AMI. The report is as follows. 1 Materials and Methods 1.1 Clinical data August 2012 to June 2014 65 cases of AMI patients admitted to our hospital, 52 males and 13 females, aged 31 to 75 years, mean (55.8 ± 10.5) years of age; both clinical manifestations Chest pain, chest tightness, shortness of breath, breathing difficulties, etc., which accompanied